Idorsia Ltd (SW:IDIA) — Market Cap & Net Worth
Market Cap & Net Worth: Idorsia Ltd (IDIA)
Idorsia Ltd (SW:IDIA) has a market capitalization of $1.03 Billion (CHF814.02 Million) as of August 1, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #8642 globally and #119 in its home market, demonstrating a 0.66% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Idorsia Ltd's stock price CHF6.12 by its total outstanding shares 253983453 (253.98 Million). See Idorsia Ltd capital spending ratio to understand how much of operating cash flow is reinvested back into capital assets.
Idorsia Ltd Market Cap History: 2017 to 2026
Idorsia Ltd's market capitalization history from 2017 to 2026. Data shows change from $8.17 Billion to $1.96 Billion (-8.42% CAGR).
Idorsia Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Idorsia Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.18x
Idorsia Ltd's market cap is 6.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $8.17 Billion | $158.09 Million | -$14.27 Million | 51.69x | N/A |
| 2018 | $5.21 Billion | $60.62 Million | -$386.39 Million | 85.92x | N/A |
| 2019 | $9.61 Billion | $23.82 Million | -$494.65 Million | 403.62x | N/A |
| 2020 | $8.19 Billion | $71.76 Million | -$445.12 Million | 114.20x | N/A |
| 2021 | $5.99 Billion | $35.35 Million | -$634.60 Million | 169.32x | N/A |
| 2022 | $4.31 Billion | $97.10 Million | -$827.90 Million | 44.38x | N/A |
| 2023 | $678.81 Million | $152.39 Million | -$297.92 Million | 4.45x | N/A |
| 2024 | $263.95 Million | $112.51 Million | -$263.76 Million | 2.35x | N/A |
| 2025 | $1.37 Billion | $221.00 Million | -$112.00 Million | 6.18x | N/A |
Competitor Companies of IDIA by Market Capitalization
Companies near Idorsia Ltd in the global market cap rankings as of August 1, 2026.
Key companies related to Idorsia Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Idorsia Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Idorsia Ltd's market cap moved from $8.17 Billion to $ 1.96 Billion, with a yearly change of -8.42%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF1.96 Billion | +43.71% |
| 2025 | CHF1.37 Billion | +417.64% |
| 2024 | CHF263.95 Million | -61.12% |
| 2023 | CHF678.81 Million | -84.25% |
| 2022 | CHF4.31 Billion | -28.00% |
| 2021 | CHF5.99 Billion | -26.96% |
| 2020 | CHF8.19 Billion | -14.76% |
| 2019 | CHF9.61 Billion | +84.59% |
| 2018 | CHF5.21 Billion | -36.27% |
| 2017 | CHF8.17 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Idorsia Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.03 Billion USD |
| MoneyControl | $1.03 Billion USD |
| MarketWatch | $1.03 Billion USD |
| marketcap.company | $1.03 Billion USD |
| Reuters | $1.03 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more